NLRP3 and cancer: To explore this mechanism in human cells, we first primed monocyte-derived macrophages from cancer-free TET2delA carriers (Ly9, Ly11, and Ly14) and controls (Ly8 and an unrelated control) with lipopolysaccharide (LPS) and interferon-γ, followed by stimulation with NLRP3 inflammasome activators.